Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
The small-molecule oncology player zeroes in on its first commercial opportunity.
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Upcoming data from Roche/Ionis and Wave Life Sciences will be an important test of potentially disease-modifying candidates.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Krystal Biotech shares surged after positive data with its epidermolysis bullosa project, KB103, in just two patients. Now it needs to repeat the trick.